Today's guest is Dr. Mark Kiel, Chief Science Officer and Founder at Genomenon. Genomenon is a genomics intelligence company that unlocks real-world evidence from biomedical literature to help pharmaceutical and clinical diagnostics companies inform precision medicine, accelerate patient diagnosis, and guide trial design and label expansion. Mark joins Emerj Editorial Director Matthew DeMello to explore how AI can streamline the extraction, organization, and interpretation of genomic and clinical data, enabling faster, more accurate decision-making in pharmaceutical R&D. He also shares practical approaches to integrating AI with human curation, improving workflow efficiency, and scaling insights for rare disease diagnosis, trial design, and drug development strategy. This episode is sponsored by Genomenon. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the 'AI in Business' podcast!

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related